摘要
目的：本研究旨在观察darbepoetin α（一种红细胞生成刺激蛋白，ESP）能否改善有症状性慢性心力衰竭（CHF）伴贫血患者的运动耐量。背景：贫血在CHF患者中较为常见。方法：在此项多中心、随机、双盲、安慰剂对照研究中，伴有贫血（血红蛋白90～120g／L）的CHF患者接受安慰剂（n=22）或darbepoetind（n=19）皮下注射，初始剂量为0．75μg／kg，每2周1次，持续26周。主要终点是从基线到27周时以峰值耗氧量[ml／（min·kg体重）】测量的运动耐量的变化。其他终点包括：绝对峰值耗氧量、运动持续时间以及健康相关生活质量的变化。
Objectives： This study sought to investigate whether darbepoetin alfa, an erythropoiesis-stimulating protein（ESP）, improves exercise capacity in patients with symptomatic chronic heart failure（CHF） and anemia. Background： Anemia is common in patients with CHF. Methods： In a multicenter, randomized, double-blind, placebo-controlled study, CHF patients with anemia（hemoglobin ≥9.0 to ≤ 12.0 g/dl） received subcutaneous placebo（n=22） or darbepoetin alfa（n = 19） at a starting dose of 0. 75 p,g/kg every 2 weeks for 26 weeks. The primary end point was change in exercise tolerance from baseline to week 27 as measured by peak oxygen uptake（ml/min/kg body weight） .
